Natural COVID Immunity is Real

Natural COVID Immunity is Real has been a member of Linktree for 5 years and joined in June 2021. Resources Natural.Immunity has populated their site with include: • Suggest a study for this list • SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy • Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection • T cells recognize recent SARS-CoV-2 variants • Immunity after SARS-CoV-2 infections • Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 • Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection • SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans • Risk of reinfection after seroconversion to SARS-CoV-2: A population-based propensity-score matched cohort study • Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy • New national surveillance of possible COVID-19 reinfection, published by PHE • SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity • Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells • Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations • Antibodies Can Last for More Than 1 Year After SARS-CoV-2 Infection: A Follow-Up Study From Survivors of COVID-19 • SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) • Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection • (PREPRINT) Necessity of COVID-19 vaccination in previously infected individuals • (PREPRINT) Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection • (PREPRINT) Protracted yet coordinated differentiation of long-lived SARS-CoV-2-specific CD8+ T cells during COVID-19 convalescence • (PREPRINT) Effectiveness of the BNT162b2 vaccine in preventing COVID-19 in the working age population – first results from a cohort study in Southern Sweden • (PREPRINT) Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel • (PREPRINT) Antibody Evolution after SARS-CoV-2 mRNA Vaccination • (PREPRINT) Neutralization of VOCs including Delta one year post COVID-19 or vaccine • (PREPRINT) Durability of SARS-CoV-2-specific T cell responses at 12-months post-infection • (PREPRINT) Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections | medRxiv • (PREPRINT) Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection | medRxiv